AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 159 filers reported holding AKERO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,184,804 | -7.6% | 43,195 | -14.7% | 0.00% | 0.0% |
| Q2 2023 | $2,363,402 | +120.0% | 50,619 | +80.3% | 0.00% | +100.0% |
| Q1 2023 | $1,074,379 | -26.4% | 28,081 | +5.4% | 0.00% | -50.0% |
| Q4 2022 | $1,459,817 | +231.0% | 26,639 | +105.3% | 0.00% | – |
| Q3 2022 | $441,000 | +261.5% | 12,976 | +1.2% | 0.00% | – |
| Q2 2022 | $122,000 | -23.3% | 12,827 | +14.8% | 0.00% | – |
| Q1 2022 | $159,000 | -30.6% | 11,178 | +3.1% | 0.00% | – |
| Q4 2021 | $229,000 | -66.4% | 10,838 | -64.5% | 0.00% | – |
| Q3 2021 | $682,000 | +166.4% | 30,572 | +195.8% | 0.00% | – |
| Q2 2021 | $256,000 | -21.5% | 10,337 | -7.8% | 0.00% | – |
| Q1 2021 | $326,000 | -55.6% | 11,215 | -60.7% | 0.00% | – |
| Q4 2020 | $735,000 | +141.8% | 28,503 | +188.5% | 0.00% | – |
| Q3 2020 | $304,000 | – | 9,879 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 103,816 | $5,251,013 | 6.02% |
| Boxer Capital, LLC | 1,676,733 | $84,809,155 | 4.52% |
| Redmile Group, LLC | 1,769,684 | $89,510,617 | 4.26% |
| Ghost Tree Capital, LLC | 250,000 | $12,645,000 | 4.16% |
| Logos Global Management LP | 600,000 | $30,348,000 | 4.05% |
| COMMODORE CAPITAL LP | 565,000 | $28,577,700 | 3.34% |
| Yiheng Capital Management, L.P. | 1,221,674 | $61,792,271 | 3.15% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,116,000 | 3.07% |
| Atlas Venture Life Science Advisors, LLC | 359,251 | $18,170,915 | 2.81% |
| Perceptive Advisors | 1,619,425 | $81,910,517 | 2.73% |